PER-045-20招募中未知
AN OPEN LABEL PHASE 2A STUDY TO ASSESS THE EFFICACY, SAFETY, TOLERABILITY AND PHARMACOKINETICS OF (+)-SJ000557733 (SJ733), WITH OR WITHOUT COMBINATION WITH COBICISTAT, IN ADULT PATIENTS WITH ACUTE, UNCOMPLICATED PLASMODIUM FALCIPARUM OR VIVAX MALARIA MONO-INFECTION OVER A 42 DAY PERIOD
Rodney Kiplin Guy,0 个研究点目标入组 23 人开始时间: 2020年10月19日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
- 入组人数
- 23
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Male or female, aged 18 to 70 years of age (inclusive) at screening.
- •2. Body weight between 45 kg and 90 kg inclusive
- •3. Presence of mono-infection of P. falciparum or P. vivax confirmed by:
- •a. Fever, as defined by axillary temperature ≥ 37.5°C or
- •oral/rectal/tympanic temperature ≥ 38°C, or history of fever in the previous 24 hours (history of fever must be documented) and,
- •b. Microscopically confirmed parasite infection: 1,000 to 40,000 asexual parasite count/µL blood
- •4. Written informed consent provided by participant, in accordance with local practice. If the participant is unable to write, witnessed consent is permitted according to local ethical considerations.
- •5. Ability to swallow oral medication.
- •6. Ability and willingness to participate and to comply with the study requirements
- •7. Agreement to hospitalization for at least 102 hours and/or until malarial parasites are not detected by microscopy on 2 consecutive occasions.
- •8. Agreement to come back to the hospital on Days 7, 10 or 11, 14, 17 or 18, 21, 24 or 25, 28, 35, and 42.
- •9. A female is eligible to enter and participate in this study if she is non-pregnant, non-lactating and if she is of:
- •a. non-child bearing potential defined as: post-menopausal (12 months of spontaneous amenorrhea or <6 months of spontaneous amenorrhea with serum FSH >40 mIU/mL), pre-menopausal and has had a hysterectomy or a bilateral oophorectomy (removal of the ovaries) or a bilateral tubal ligation with medical report verification, negative pregnancy test or,
- •b. Women of child-bearing potential, has a negative pregnancy test at screening, and agrees to comply with one of the following during the treatment stage of the study and for a period of 30 days after stopping study drug:
- •i. Use of oral, implantable, or injectable hormonal contraceptive, either combined or progestogen alone used in conjunction with double barrier method as defined below.
- •ii. Use of an intrauterine device with a documented failure rate of <1% per year.
- •iii. Barrier method consisting of either condom or diaphragm.
- •iv. Male partner who is sterile prior to the female subject’s entry into the study and is the sole sexual partner for that female.
- •v. Complete abstinence from intercourse for 2 weeks prior to administration of study drug, throughout the study and for a period of 30 days after stopping study drug.
排除标准
- •1. Signs and symptoms of severe/complicated malaria according to the World Health Organization Criteria 2010 (Attachment 1: Definition of Severe Malaria)
- •2. Mixed Plasmodium infection.
- •3. Severe vomiting, defined as more than three times in the 24 hours prior to inclusion in the study, or severe diarrhea defined as 3 or more watery stools per day.
- •4. Severe malnutrition (defined as the weight-for-height being below -3 standard deviation or less than 70% of median of the NCHS/WHO normalized reference values)
- •5. Presence of a significant medical or psychiatric condition, or any other serious or chronic clinical condition requiring hospitalization, or any other condition that in the opinion of the investigator precludes participation in the study.
- •6. Female patients must not be either lactating or pregnant as demonstrated by a negative serum point-of-care pregnancy test pre-dose (the result of the pre-dose assessment must be confirmed negative prior to dosing).
- •7. Employment under the direct supervision of the investigators or study staff.
- •8. Clinically significant alterations to hematologic or clinical chemistry parameters that in the opinion of the investigator precludes participation in the study, including:
- •a. AST/ALT > 3 x upper limit of normal range (ULN) and total bilirubin is normal
- •b. AST/ALT > 2 x ULN and total bilirubin is >1 and <1.5 x ULN and conjugated bilirubin is > 35% of the total bilirubin
- •c. Total bilirubin > 1.5 x ULN
- •d. Serum creatinine levels > 2 x ULN
- •e. Hb level < 8 g/dL
- •f. Platelet level < 50,000/mm3
- •9. Participation in a clinical study of another investigational small molecule within 30 days or investigational biologic within 90 days prior to study enrollment or planning to begin such participation during the study.
- •10. Have received any antimalarial treatment (alone or in combination) in the past containing:
- •a. Piperaquine, mefloquine, naphthoquine or sulphadoxine /pyrimethamine within the previous 6 weeks
- •b. Amodiaquine or chloroquine within the previous 4 weeks
- •c. Any artemisinin (artesunate, artemether, arteether or dihydroartemisinin) quinine, halofantrine, lumefantrine and any other anti-malarial treatment or antibiotics with antimalarial activity (including cotrimoxazole, tetracyclines, quinolones and fluoroquinolones, and azithromycin) within the past 14 days
- •11. Any medication from a list of prohibited medications as provided in Section 7.6.
研究者
相似试验
进行中（未招募）
1 期
EVALUATION OF EFFICACY AND SAFETY OF STANDARD CHEMOTHERAPY IN COMBINATION WITH NILOTINIB IN PATIENTS OF 55 YEARS AND OLDER WITH PHILADELPHIA CHROMOSOME POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA.EUCTR2010-022855-46-DEDekan des Fachbereichs Medizin der Goethe Universität, represented by the Coordinating Investigator75
进行中（未招募）
不适用
AN OPEN LABEL PHASE II STUDY TO EVALUATE THE EFFICACY AND SAFETY OF INDUCTION AND CONSOLIDATION THERAPY WITH DASATINIB IN COMBINATION WITH CHEMOTHERAPY IN PATIENTS AGED 55 YEARS AND OVER WITH PHILADELPHIA CHROMOSOME POSITIVE (PH+ OR BCR-ABL+) ACUTE LYMPHOBLASTIC LEUKEMIA (ALL).EWALL-PH-01 - EWAPhiladelphia chromosome positive Acute Lymphoblastic LeukemiaEUCTR2006-005694-21-DECH-Versailles55
进行中（未招募）
1 期
AN OPEN LABEL PHASE II STUDY TO EVALUATE THE EFFICACY AND SAFETY OF INDUCTION AND CONSOLIDATION THERAPY WITH DASATINIB IN COMBINATION WITH CHEMOTHERAPY IN PATIENTS AGED 55 YEARS AND OVER WITH PHILADELPHIA CHROMOSOME POSITIVE (PH+ OR BCR-ABL+) ACUTE LYMPHOBLASTIC LEUKEMIA (ALL).EWALL-PH-01 - EWAPhiladelphia chromosome positive Acute Lymphoblastic LeukemiaEUCTR2006-005694-21-FRCH-Versailles55
进行中（未招募）
1 期
EVALUATION OF EFFICACY AND SAFETY OF STANDARD CHEMOTHERAPY IN COMBINATION WITH NILOTINIB IN PATIENTS OF 55 YEARS AND OLDER WITH PHILADELPHIA CHROMOSOME POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA.Philadelphia chromosome positive Acute Lymphoblastic Leukemia in elderly Patients (55 years and older)MedDRA version: 17.0Level: LLTClassification code 10000845Term: Acute lymphoblastic leukemiaSystem Organ Class: 100000004864EUCTR2010-022855-46-ESFundación PETHEMA79
进行中（未招募）
1 期
A Study to Evaluate the Efficacy and Safety of Ustekinumab in patients with Behçet diseaseEUCTR2015-002190-37-FRASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)30